Business Context and Reporting Period
This Form 8-K Current Report was filed by Crinetics Pharmaceuticals, Inc. on September 13, 2024. The filing addresses a material corporate governance event regarding the departure of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the separation of James Hassard from the Company. Mr. Hassard will cease serving as Chief Commercial Officer effective October 14, 2024.
Management Commentary and Contingencies
- Compensatory Arrangements: Pursuant to the Employment Agreement dated February 16, 2022, Mr. Hassard is entitled to payments and benefits associated with a termination without cause.
- Conditions: These benefits are subject to Mr. Hassard's execution of a release of claims in favor of the Company, its affiliates, and their respective officers and directors.
- Reference: The specific terms of the Employment Agreement are incorporated by reference from Exhibit 10.24 of the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Investor Verification Checklist
- Verify the exact terms of the "termination without cause" severance package in the referenced Employment Agreement (Exhibit 10.24 of the 2023 10-K).
- Confirm the status of the release of claims required for Mr. Hassard to receive benefits.
- Monitor subsequent filings for the appointment of an interim or permanent replacement for the Chief Commercial Officer role.
- Review the Company's 10-K and 10-Q filings for the most recent financial performance data, as this 8-K contains none.